Literature DB >> 27381221

Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG).

M R S Siddiqui1, K L Gormly2, J Bhoday1, S Balyansikova3, N J Battersby3, M Chand4, S Rao3, P Tekkis5, A M Abulafi6, G Brown7.   

Abstract

AIM: To investigate whether the magnetic resonance imaging (MRI) tumour regression grading (mrTRG) scale can be taught effectively resulting in a clinically reasonable interobserver agreement (>0.4; moderate to near perfect agreement).
MATERIALS AND METHODS: This study examines the interobserver agreement of mrTRG, between 35 radiologists and a central reviewer. Two workshops were organised for radiologists to assess regression of rectal cancers on MRI staging scans. A range of mrTRGs on 12 patient scans were used for assessment.
RESULTS: Kappa agreement ranged from 0.14-0.82 with a median value of 0.57 (95% CI: 0.37-0.77) indicating good overall agreement. Eight (26%) radiologists had very good/near perfect agreement (κ>0.8). Six (19%) radiologists had good agreement (0.8≥κ>0.6) and a further 12 (39%) had moderate agreement (0.6≥κ>0.4). Five (16%) radiologists had a fair agreement (0.4≥κ>0.2) and two had poor agreement (0.2>κ). There was a tendency towards good agreement (skewness: 0.92). In 65.9% and 90% of cases the radiologists were able to correctly highlight good and poor responders, respectively.
CONCLUSIONS: The assessment of the response of rectal cancers to chemoradiation therapy may be performed effectively using mrTRG. Radiologists can be taught the mrTRG scale. Even with minimal training, good agreement with the central reviewer along with effective differentiation between good and intermediate/poor responders can be achieved. Focus should be on facilitating the identification of good responders. It is predicted that with more intensive interactive case-based learning a κ>0.8 is likely to be achieved. Testing and retesting is recommended.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27381221     DOI: 10.1016/j.crad.2016.05.005

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  16 in total

1.  T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Sungwon Kim; Kyunghwa Han; Nieun Seo; Hye Jin Kim; Myeong-Jin Kim; Woong Sub Koom; Joong Bae Ahn; Joon Seok Lim
Journal:  Eur Radiol       Date:  2018-06-01       Impact factor: 5.315

Review 2.  How Should Imaging Direct/Orient Management of Rectal Cancer?

Authors:  Jemma Bhoday; Svetlana Balyasnikova; Anita Wale; Gina Brown
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

3.  Histopathological and radiological reporting in rectal cancer: concepts and controversies, facts and fantasies.

Authors:  S Balyasnikova; N Haboubi; B Moran; G Brown
Journal:  Tech Coloproctol       Date:  2016-12-07       Impact factor: 3.781

4.  Combined artificial intelligence and radiologist model for predicting rectal cancer treatment response from magnetic resonance imaging: an external validation study.

Authors:  Natally Horvat; Harini Veeraraghavan; Caio S R Nahas; David D B Bates; Felipe R Ferreira; Junting Zheng; Marinela Capanu; James L Fuqua; Maria Clara Fernandes; Ramon E Sosa; Vetri Sudar Jayaprakasam; Giovanni G Cerri; Sergio C Nahas; Iva Petkovska
Journal:  Abdom Radiol (NY)       Date:  2022-06-16

5.  A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer.

Authors:  Xiaolin Pang; Peiyi Xie; Li Yu; Haiyang Chen; Jian Zheng; Xiaochun Meng; Xiangbo Wan
Journal:  Br J Cancer       Date:  2022-04-06       Impact factor: 9.075

Review 6.  Rectal MRI radiomics for predicting pathological complete response: Where we are.

Authors:  Joao Miranda; Gary Xia Vern Tan; Maria Clara Fernandes; Onur Yildirim; John A Sims; Jose de Arimateia Batista Araujo-Filho; Felipe Augusto de M Machado; Antonildes N Assuncao-Jr; Cesar Higa Nomura; Natally Horvat
Journal:  Clin Imaging       Date:  2021-11-16       Impact factor: 2.420

7.  Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.

Authors:  Francesco Sclafani; Gina Brown; David Cunningham; Andrew Wotherspoon; Larissa Sena Teixeira Mendes; Svetlana Balyasnikova; Jessica Evans; Clare Peckitt; Ruwaida Begum; Diana Tait; Josep Tabernero; Bengt Glimelius; Susana Roselló; Janet Thomas; Jacqui Oates; Ian Chau
Journal:  Br J Cancer       Date:  2017-09-21       Impact factor: 7.640

8.  Clinical utility of radiomics at baseline rectal MRI to predict complete response of rectal cancer after chemoradiation therapy.

Authors:  Iva Petkovska; Florent Tixier; Eduardo J Ortiz; Jennifer S Golia Pernicka; Viktoriya Paroder; David D Bates; Natally Horvat; James Fuqua; Juliana Schilsky; Marc J Gollub; Julio Garcia-Aguilar; Harini Veeraraghavan
Journal:  Abdom Radiol (NY)       Date:  2020-11

9.  Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer.

Authors:  Marco Rengo; Simona Picchia; Simona Marzi; Davide Bellini; Damiano Caruso; Mauro Caterino; Maria Ciolina; Domenico De Santis; Daniela Musio; Vincenzo Tombolini; Andrea Laghi
Journal:  Oncotarget       Date:  2017-10-10

10.  A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.

Authors:  Nick J Battersby; Mit Dattani; Sheela Rao; David Cunningham; Diana Tait; Richard Adams; Brendan J Moran; Shelize Khakoo; Paris Tekkis; Shahnawaz Rasheed; Alex Mirnezami; Philip Quirke; Nicholas P West; Iris Nagtegaal; Irene Chong; Anguraj Sadanandam; Nicola Valeri; Karen Thomas; Michelle Frost; Gina Brown
Journal:  Trials       Date:  2017-08-29       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.